BiomX Inc. announced on July 8, 2025, the publication of a peer-reviewed article in Nature Communications, titled 'Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.' This publication features previously unreported antimicrobial efficacy data from the Phase 1b/2a clinical trial.
The article provides significant third-party validation for BiomX's phage therapy platform, showcasing new analyses from Part 1 of the study. These analyses demonstrated that BX004 achieved an approximately 500-fold (2.7 log₁₀) greater bacterial reduction compared to placebo in CF patients.
Notably, the data highlighted that no bacterial resistance to BX004 emerged during the trial, addressing a critical limitation of traditional antibiotics. The findings from Part 1 were consistent with results observed in Part 2 of the study, reinforcing the strength of the BX004 program as it advances into a Phase 2b trial with topline results expected in Q1 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.